CV Sciences (CVSI) Other Non-Current Assets (2013 - 2026)
CV Sciences (CVSI) reported Other Non-Current Assets of $47000.0 for Q1 2026, down 52.53% on a YoY basis from $99000.0 in Q1 2025, and little changed sequentially from $47000.0 in Q4 2025.
CV Sciences (CVSI) Other Non-Current Assets (2013 - 2026) Analysis & Trends
CV Sciences (CVSI) has 13 years of Other Non-Current Assets data on file, last reported at $47000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 52.53% year-over-year to $47000.0; the trailing twelve-month figure through Mar 2026 stood at $47000.0 (down 52.53% YoY), and the FY2025 full-year result was $47000.0, changed N/A from the prior year.
- Other Non-Current Assets steadied at $47000.0 in Q1 2026, from $47000.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $626000.0 in Q1 2022 to a low of $47000.0 in Q3 2025.
- A 5-year average of $294187.5 and a median of $270000.0 in 2023 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets grew 24.95% in 2022 and sank 69.48% in 2025, its largest moves.
- Tracing CVSI's Other Non-Current Assets over 5 years: stood at $505000.0 in 2022, then plunged by 41.39% to $296000.0 in 2023, then plunged by 47.97% to $154000.0 in 2024, then slumped by 69.48% to $47000.0 in 2025, then changed by 0.0% to $47000.0 in 2026.
- Business Quant data shows CVSI's Other Non-Current Assets at $47000.0 in Q1 2026, $47000.0 in Q4 2025, and $47000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 1.79 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 233.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 295.00 Mn |
| 10 | CV Sciences | 3.74 Mn | 3.43 Mn | 1.56 Mn | 47,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47,000.00 |
| Dec 31, 2025 | 47,000.00 |
| Sep 30, 2025 | 47,000.00 |
| Jun 30, 2025 | 72,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Sep 30, 2024 | 154,000.00 |
| Jun 30, 2024 | 202,000.00 |
| Mar 31, 2024 | 244,000.00 |
| Dec 31, 2023 | 296,000.00 |
| Sep 30, 2023 | 348,000.00 |
| Jun 30, 2023 | 401,000.00 |
| Mar 31, 2023 | 452,000.00 |
| Dec 31, 2022 | 505,000.00 |
| Sep 30, 2022 | 557,000.00 |
| Jun 30, 2022 | 610,000.00 |
| Mar 31, 2022 | 626,000.00 |
| Dec 31, 2021 | 678,000.00 |
| Sep 30, 2021 | 730,000.00 |
| Jun 30, 2021 | 501,000.00 |
| Mar 31, 2021 | 501,000.00 |